Research Grade Lesofavumab (DVV03805)

Catalog No.

DVV03805

Description

Lesofavumab is a Recombinant monoclonal antibody to Influenza B virus hemagglutinin. Lesofavumab is a human monoclonal antibody that can be potentially used in the treatment of Influenza B infection. Genentech, a subsidiary of Roche, is developing lesofavumab (RG 6024), a monoclonal antibody, for the treatment of influenza B infections.

Expression system

Mammalian Cells

Species reactivity

Influenza B virus

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

HA/Hemagglutinin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03461

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

RG6024, RG 6024, MHAB5553A, RG70026, RO7045557, CAS: 1807960-57-1

Clone ID

Lesofavumab

In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection, PMID: 30796434

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers, PMID: 28559255

Document Download

Research Grade Lesofavumab.pdf